🔗 Share this article

Elected officials have issued warnings that the United Kingdom's negotiated accords with Washington are "fundamentally unstable." This comes after revelations that a recently announced deal on medicines, which promises zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond limited headline terms contained within government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, promoted as a "generational" achievement, exists as an "statement of intent" without detailed provisions. Observers point out that the press releases from the UK and US governments frame the deal in markedly contrasting terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement highlights the expectation for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to increase medicine costs in return for nothing more than a assurance from President Trump," said David Henig, a trade expert. "History shows he has form for not honouring his word."

Broader Instability and a Paused Tech Deal

Anxieties have been intensified by Washington's move to put on ice the £31bn "tech prosperity deal", which was previously called "a transformative pact" in the bilateral relationship. The US cited a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

In a separate development, concessions agreed to for British farmers as part of an earlier tariff deal have not been formally ratified by the US, despite a looming January deadline. "Our understanding is that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have admitted unease that the government's agreements with the US are flimsy and unreliable. One minister reportedly said the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, remarked: "Perhaps most shocking than Trump's temper tantrums is the UK government's credulous faith that his administration is a good faith actor. The NHS is not a bargaining chip."

Government Downplays Risks, Points to Gains

Officials have sought to reduce the risk of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials concede that unpredictability is a feature of dealing with the Trump administration. However, they argue that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

Yet, issues have arisen in implementing the broader trade deal. Promised access for British beef have failed to be approved, and the pledge to "eliminate duties on UK metals" has not been fulfilled, with tariffs staying at 25%.

As negotiations continue, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.